{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:18:49Z","timestamp":1778055529388,"version":"3.51.4"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.critrevonc.2015.07.012","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T19:19:45Z","timestamp":1438456785000},"page":"542-554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?"],"prefix":"10.1016","volume":"96","author":[{"given":"Laura","family":"Cannella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Mandelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2015.07.012_bib0005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2013-11-540021","article-title":"Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life","volume":"123","author":"Abel","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.07.012_bib0010","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.leu.2404576","article-title":"Fatigue in older adults with acute myeloid leukemia: predictors and associations with quality of life and functional status","volume":"21","author":"Alibhai","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.07.012_bib0015","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00520-013-2044-8","article-title":"A pilot phase II RCT. of a home-based exercise intervention for survivors of AML","volume":"22","author":"Alibhai","year":"2014","journal-title":"Supportive Care Cancer: Off. J. Multinational Assoc. Supportive Care Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.07.012_bib0020","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2006-08-041152","article-title":"End points to establish the efficacy of new agents in the treatment of acute leukemia","volume":"109","author":"Appelbaum","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.07.012_bib0025","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European leukemia net recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2015.07.012_bib0030","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1056\/NEJMp1200070","article-title":"Defining patient-centered medicine","volume":"366","author":"Bardes","year":"2012","journal-title":"N. E. J. Med."},{"issue":"34","key":"10.1016\/j.critrevonc.2015.07.012_bib0035","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.2012.42.5967","article-title":"Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology","volume":"30","author":"Basch","year":"2012","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2015.07.012_bib0040","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2015.07.012_bib0045","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2007-12-129379","article-title":"Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980 to the early 21st century","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.07.012_bib0050","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11136-010-9793-3","article-title":"Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers","volume":"20","author":"Brundage","year":"2011","journal-title":"Qual. Life Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2015.07.012_bib0055","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11136-012-0252-1","article-title":"Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards","volume":"22","author":"Brundage","year":"2013","journal-title":"Qual. Life Res.: Int. J. Qual. Life Aspects Treat. Care Rehabil."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.07.012_bib0060","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/leu.2012.360","article-title":"Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial","volume":"27","author":"Burnett","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.07.012_bib0065","first-page":"1","article-title":"Treatment of acute myeloid leukemia: are we making progress?","volume":"2012","author":"Burnett","year":"2012","journal-title":"ASH Educ. Prog. Book"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.07.012_bib0070","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/cncr.26341","article-title":"Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia\/lymphoma: results of a randomized clinical trial","volume":"118","author":"Cabanillas","year":"2012","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2015.07.012_bib0075","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the consort pro extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA: J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.critrevonc.2015.07.012_bib0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1586\/17474086.2.1.69","article-title":"Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes","volume":"2","author":"Caocci","year":"2009","journal-title":"Expert Rev. Hematol."},{"issue":"9583","key":"10.1016\/j.critrevonc.2015.07.012_bib0085","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.07.012_bib0090","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jpainsymman.2007.06.013","article-title":"Effects of a walking intervention on fatigue-related experiences of hospitalized acute myelogenous leukemia patients undergoing chemotherapy: a randomized controlled trial","volume":"35","author":"Chang","year":"2008","journal-title":"J. Pain Symptom Manage."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.07.012_bib0095","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/annonc\/mdl494","article-title":"Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making","volume":"18","author":"Efficace","year":"2007","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2015.07.012_bib0100","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3324\/haematol.11710","article-title":"Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here?","volume":"92","author":"Efficace","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.critrevonc.2015.07.012_bib0105","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2008.03.017","article-title":"Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials\u2014a systematic review to evaluate the added value in supporting clinical decision making","volume":"44","author":"Efficace","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2015.07.012_bib0110","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib","volume":"27","author":"Efficace","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.critrevonc.2015.07.012_bib0115","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.ejca.2014.04.005","article-title":"Patient-reported outcomes in randomised controlled trials of gynaecological cancers: investigating methodological quality and impact on clinical decision-making","volume":"50","author":"Efficace","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"30","key":"10.1016\/j.critrevonc.2015.07.012_bib0120","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.2014.55.3453","article-title":"Randomized phase III. Trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes","volume":"32","author":"Efficace","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2015.07.012_bib0125","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","article-title":"International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24","volume":"23","author":"Efficace","year":"2014","journal-title":"Qual. Life Res.: Inte. J. Qual. Life Aspects Treat. Care Rehabil."},{"key":"10.1016\/j.critrevonc.2015.07.012_bib0130","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.eururo.2013.10.017","article-title":"Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision making","volume":"66","author":"Efficace","year":"2014","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2015.07.012_bib0135","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.beha.2007.02.002","article-title":"Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL)","volume":"20","author":"Eichhorst","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"13","key":"10.1016\/j.critrevonc.2015.07.012_bib0140","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1200\/JCO.2006.05.6929","article-title":"Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group","volume":"25","author":"Eichhorst","year":"2007","journal-title":"J. Clin. Oncol.: Off J. Am. Soc. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.07.012_bib0145","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2141.2008.07407.x","article-title":"Patients\u2019 experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial","volume":"143","author":"Else","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2015.07.012_bib0150","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3109\/10428194.2011.649479","article-title":"Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial","volume":"53","author":"Else","year":"2012","journal-title":"Leukemia Lymphoma"},{"issue":"13","key":"10.1016\/j.critrevonc.2015.07.012_bib0155","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1470-2045(11)70242-X","article-title":"Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial","volume":"12","author":"Elter","year":"2011","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.07.012_bib0160","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jval.2014.06.005","article-title":"PRO data collection in clinical trials using mixed modes: report of the ISPOR PRO mixed modes good research practices task force","volume":"17","author":"Eremenco","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2015.07.012_bib0165","unstructured":"European Medicine Agency, 2014. Oncology Working Party. Reflection Paper on the use of patient reported outcome (PRO) measures in oncology studies. 2014. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/06\/WC500168852.pdf [Accessed August 13, 2015]."},{"issue":"14","key":"10.1016\/j.critrevonc.2015.07.012_bib0170","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.07.012_bib0175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.23642","article-title":"Myelodysplastic syndromes:update on diagnosis, risk-stratification, and management","volume":"89","author":"Garcia-Manero","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.07.012_bib0180","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2015.07.012_bib0185","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","article-title":"Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern cooperative oncology group (E1996)","volume":"114","author":"Greenberg","year":"2009","journal-title":"Blood"},{"issue":"9747","key":"10.1016\/j.critrevonc.2015.07.012_bib0190","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2015.07.012_bib0195","doi-asserted-by":"crossref","first-page":"ii49","DOI":"10.1093\/annonc\/mdm034","article-title":"Chronic lymphocytic leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"18","author":"Hallek","year":"2007","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol. ESMO"},{"issue":"18","key":"10.1016\/j.critrevonc.2015.07.012_bib0200","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2015.07.012_bib0205","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.critrevonc.2015.07.012_bib0210","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III. randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2015.07.012_bib0215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12000","article-title":"Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial","volume":"159","author":"Knauf","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2015.07.012_bib0220","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/sj.leu.2404005","article-title":"Acute leukaemia in adults: researching the patient\u2019s perspective","volume":"20","author":"Koenigsmann","year":"2006","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.critrevonc.2015.07.012_bib0225","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3324\/haematol.2009.007849","article-title":"Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973 and 2003 in Sweden","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.07.012_bib0230","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. E. J. Med."},{"issue":"15","key":"10.1016\/j.critrevonc.2015.07.012_bib0235","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"Lubbert","year":"2011","journal-title":"J. Clin. Oncol.: Off. J Am. Soc. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2015.07.012_bib0240","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","article-title":"Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European leukemia net","volume":"122","author":"Malcovati","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.07.012_bib0245","series-title":"Hematology\/the Education Program of the American Society of Hematology","first-page":"13","article-title":"Treating the \u201colder\u201d adult with acute lymphoblastic leukemia","author":"Marks","year":"2010"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.07.012_bib0250","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2010-09-308775","article-title":"Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation","volume":"117","author":"Michallet","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2015.07.012_bib0255","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"15","key":"10.1016\/j.critrevonc.2015.07.012_bib0260","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2012.466","article-title":"Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective","volume":"307","author":"PCORI","year":"2012","journal-title":"JAMA: J. Am. Med. Assoc."},{"key":"10.1016\/j.critrevonc.2015.07.012_bib0265","first-page":"CD008818","article-title":"et al. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission","volume":"10","author":"Pidala","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.critrevonc.2015.07.012_bib0270","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980 to the early 21st century","volume":"113","author":"Pulte","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.07.012_bib0275","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.leukres.2012.11.017","article-title":"Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial","volume":"37","author":"Revicki","year":"2013","journal-title":"Leukemia Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2015.07.012_bib0280","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2015.07.012_bib0285","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.07.012_bib0290","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/sj.leu.2400977","article-title":"Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy\u2013a longitudinal study","volume":"12","author":"Schumacher","year":"1998","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.07.012_bib0295","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/sj.leu.2403289","article-title":"Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome","volume":"18","author":"Sekeres","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.07.012_bib0300","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.07.012_bib0305","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.07.012_bib0310","unstructured":"US Food and Drug Administration, 2009, Guidance for Industry, Patient-reported outcome measures: use in medical product development to support labeling claims. U.S. Department of Health and Human Services Food and Drug Administration, December, 2009. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf [Accessed August 13, 2015]"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.07.012_bib0315","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.blre.2014.07.001","article-title":"Acute Promyelocytic leukemia: what is the new standard of care?","volume":"28","author":"Watts","year":"2014","journal-title":"Blood Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.07.012_bib0320","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","article-title":"Measuring the symptom burden associated with the treatment of chronic myeloid leukemia","volume":"122","author":"Williams","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2015.07.012_bib0325","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","article-title":"Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712","volume":"29","author":"Woyach","year":"2011","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.07.012_bib0330","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2011.41.5646","article-title":"Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies","volume":"31","author":"Woyach","year":"2013","journal-title":"J. Cin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2015.07.012_bib0335","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.23610","article-title":"Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European society for blood and marrow transplantation-intergroup study","volume":"89","author":"de Wreede","year":"2014","journal-title":"Am. J. Hematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815300123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815300123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T19:43:26Z","timestamp":1599421406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815300123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1040842815300123"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.07.012","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}